Oppenheimer Remains Bullish On Integra Lifesciences, $57 PT
In a research note published today, analyst Steven Lichtman of Oppenheimer assigned an Outperform rating on Integra Lifesciences (NASDAQ:IART) with a $57 price target.
Lichtman commented: “During our recent time on the road with IART senior management, the focus was on the progress being made rationalizing the company’s operating structure, where it will focus on business development efforts and new growth opportunities including DFU, extremities (ankle/shoulder) and international markets. No specific comments were made about the ongoing FDA re-inspection of the Anasco facility, but we continue to believe IART’s progress will lead to less required compliance spend looking forward. We look for 5%+ sales growth next few years and 12-13% EPS growth (15% on a GAAP basis) with upside potential from pipeline call options.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Steven Lichtman has a total average return of 3.4% and a 56.5% success rate. Lichtman has a 10.8% average return when recommending IART, and is ranked #1477 out of 3300 analysts.